New Delhi, Jan 18: Drug major Cipla on Wednesday said it has launched a diagnostic device for various conditions including diabetes, infectious diseases and thyroid function.
The product — Cippoint — a point-of-care testing device offers a wide range of testing parameters including cardiac markers, diabetes, infectious diseases, fertility, thyroid function, inflammation, metabolic markers, and coagulation markers, the Mumbai-based drug maker said in a statement.
The device is approved by the European In-Vitro Diagnostic Device Directive, thus ensuring reliable testing solutions, it added.
“We are actively working towards delivering innovative solutions that enable prompt and effective diagnosis, thereby plugging gaps in the diagnostic ecosystem. This development further strengthens our vision of supporting patients across the healthcare continuum,” Cipla One India Business CEO Achin Gupta said.
The company said with the device the company has expanded its product offerings for diagnostics laboratories and aims to bridge the current gap in the diagnostic ecosystem in India by providing reliable and accurate tests at affordable prices.
Cippoint will allow healthcare professionals to get test results in 3 to 15 minutes, thus enabling a faster clinical decision-making process.
Cippoint has an automated system and user-friendly interface which can be used even in rural areas, mobile vans, and remote areas with limited infrastructure, Cipla said. (PTI)
Follow our WhatsApp channel
